Bion-1301 phase 3
WebMay 19, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular … WebNov 14, 2024 · Once an RP2D is identified, Phase 2 of the study will open and continue to evaluate the safety and preliminary efficacy of BION-1301 administered at selected dose …
Bion-1301 phase 3
Did you know?
Web1 day ago · SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development... WebApr 11, 2024 · Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers Published: April 11, 2024 at 8:00 a.m. ET
WebJun 6, 2024 · Parts 1 and 2 assess BION-1301 in HV, and Part 3 will assess BION-1301 in patients with IgAN. Parts 1 and 2 are double-blind, randomized, placebo-controlled single … WebBION-1301 Publications. Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy ISN World Congress of Nephrology 2024 March 2024. A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA …
WebJun 8, 2024 · Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) is evaluating the safety, tolerability, PK and pharmacodynamics … WebAug 31, 2024 · BION-1301 offers them a second shot on goal with superior potency. Key readouts for both assets are approaching in 2024. ... Ongoing PROTECT phase 3 study met its interim primary endpoint at 49.8% ...
WebNov 4, 2024 · Chinook will host a live conference call and webcast today at 4:30 pm EDT to discuss the data from Cohort 1 of Part 3 of Chinook’s ongoing phase 1/2 study of BION-1301 in patients with IgAN as ...
WebMay 3, 2024 · Parts 1 and 2 of the Phase 1/2 study (NCT03945318) assessing single and multiple ascending doses of BION-1301 in HV are complete. Part 3 is an ongoing, open-label, multicohort design in patients with IgAN treated with BION-1301 for up to 1 year. chinny surinaamse broodjesWebMay 19, 2024 · Data generated from this phase 1/2 study will inform the design of a phase 3 trial of BION-1301 for patients with IgAN that Chinook plans to initiate in 2024. granite peaks high school utahWebNov 4, 2024 · FR-PO659 – Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 2 clinical ... granite peak ski team wausau wisconsinWebBION-1301 is a proprietary monoclonal antibody therapeutic targeting APRIL, which is being evaluating for the treatment of IgA nephropathy. Preclinical studies have demonstrated that BION-1301 binds to a … granite peaks motor company pleasant grove utWebPart 3 of Chinook's phase 1b study of BION-1301 is currently enrolling IgAN patients in an open-label setting, and Chinook expects to present a small subset of interim patient data in an oral presentation at the 58 th ERA-EDTA Congress in June, as well as additional patient data at the ASN Kidney Week 2024 in November. • granite peaks lifelong learningWebNov 4, 2024 · Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses of open-label BION-1301 treatment in … granite peak snowboard camp 2017WebNov 14, 2024 · Once an RP2D is identified, Phase 2 of the study will open and continue to evaluate the safety and preliminary efficacy of BION-1301 administered at selected dose level(s). The population for this study will consist of adults with relapsed or refractory MM whose disease has progressed after at least 3 prior systemic therapies. granite peak motor company